- Home
- SLN
as 05-30-2025 4:00pm EST
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
| Founded: | 1994 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 165.3M | IPO Year: | N/A |
| Target Price: | $32.60 | AVG Volume (30 days): | 189.3K |
| Analyst Decision: | Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.52 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.97 - $22.46 | Next Earning Date: | 05-08-2025 |
| Revenue: | $27,701,000 | Revenue Growth: | -16.00% |
| Revenue Growth (this year): | -25.23% | Revenue Growth (next year): | N/A |
Latest Silence Therapeutics Plc American Depository Share News
SLN Breaking Stock News: Dive into SLN Ticker-Specific Updates for Smart Investing
Zacks
12 days ago
Wall Street Analysts Believe Silence Therapeutics (SLN) Could Rally 590.66%: Here's is How to Trade
Simply Wall St.
17 days ago
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
Simply Wall St.
23 days ago
We're Keeping An Eye On Silence Therapeutics' (NASDAQ:SLN) Cash Burn Rate
Simply Wall St.
23 days ago
Silence Therapeutics First Quarter 2025 Earnings: Misses Expectations
Business Wire
25 days ago
Silence Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
Business Wire
a month ago
Silence Therapeutics Welcomes Tim McInerney to Board of Directors
Insider Monkey
a month ago
Silence Therapeutics plc (SLN): Among Takeover Rumors Hedge Funds Are Buying
Simply Wall St.
2 months ago
3 Promising Penny Stocks With Market Caps Under $200M
Compare SLN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLN Silence Therapeutics Plc American Depository Share - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.